Razi Ingber, RedHill Biopharma and Chief Financial Officer, said: “We are very pleased to reach this smooth conclusion, which strengthens RedHill’s cash position and greatly enhances our ability to manage our cash. The Agreement eliminates substantially all encumbrances related to the previous Movantik divestment and Credit Agreements, allowing us to better focus on our R&D and commercial activities and return the Company to a growth mode. This is a new chapter for RedHill.”

Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 – 19, 2024 at Imperial College in London, U.K. reports Addex Therapeutics.

Medsenic SAS, subsidiary of BioSenic SA, is exploring the therapeutic use of ATO in several indications with clinical success. The company is also making significant progress in elucidating the mechanisms by which ATO modulates immune responses and the ability of certain metal ions to enhance this therapeutic potential.

IXCHIQ ® is the world’s only licensed chikungunya vaccine available to address this unmet medical need. In accordance with the International Recognition Procedure (IRP)3, Valneva has also submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA). An additional marketing authorization application is under review by the Brazilian Health Regulatory Agency (ANVISA) to make the vaccine available in certain Low- and Middle-Income Countries (LMIC), with potential approval in 2024.